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Background: Mastitis is one of the most important diseases affecting dairy sheep. Antimicrobial drugs are often
administered directly through teat to treat or prevent this disease, but data on drug distribution within glandular
tissue are scarce and it cannot be estimated from concentrations in milk. Thus, the aim of this study was to
investigate systemic and mammary gland distribution of enrofloxacin after intramammary administration. The
drug was administered to 6 healthy lactating Assaf sheep with an injector containing an enrofloxacin preparation
(1 g drug/5 g ointment). Blood samples were collected at 0, 30, 60, 90, 120, 150 and 180 min. Animals were then
sedated and sacrificed, and glandular tissue samples were obtained from treated udders at 2, 4, 6 and 8 cm height.
Enrofloxacin concentrations were measured in plasma and tissue samples by UV high-performed liquid chromatography.
Results: Mean enrofloxacin plasma concentrations were below 0.5 μg/mL. Mean tissue concentrations decreased in
mammary gland with vertical distance from the teat, ranging from 356.6 μg/g at 2 cm to 95.60 μg/g at the base of the
udder. Glandular tissue concentrations best fitted to a decreasing monoexponential model, and showed a good
correlation with an ex vivo model previously developed.
Conclusions: Enrofloxacin concentrations were effective in the entire glandular tissue against the main pathogens
causing mastitis in sheep. These results suggest that this drug may be suitable to treat mastitis in sheep by
intramammary administration.
Keywords: Enrofloxacin, Sheep, Intramammary, Systemic, Glandular tissue, DispositionBackground
Mastitis is one of the most important and costly diseases
affecting dairy sheep, resulting in substantial health and
economic problems worldwide. The two major forms of
this disease are clinical mastitis, which results in signs of
inflammation in infected mammary glands, changes in
milk composition and altered systemic condition of the
animal, and subclinical mastitis, without readily apparent
signs in animals but with altered somatic cell count of
the milk. From both types of mastitis, the subclinical
one is not only very frequent but also economically im-
portant as it reduces the quantity and quality of milk* Correspondence: amsahp@unileon.es
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unless otherwise stated.produced. Prevalence values of this form average 5-30%
in small ruminants, whereas for clinical mastitis they are
generally lower than 5% [1-3].
Although a variety of microorganisms can cause mas-
titis in sheep, Staphylococcus spp. are the most fre-
quently isolated agents involved in both acute clinical
and subclinical forms. Other pathogens such as Entero-
bacteriaceae, Streptococcus spp., Mycoplasma spp.,
Mannheimia haemolytica or Pseudomonas spp. are also
found.
Fluoroquinolones are considered among the most ef-
fective drugs for the treatment of bacterial infections,
and they should be reserved to those situations with
poor response to other antimicrobial agents, in order to
prevent increasing the risk of quinolone-resistant bac-
teria. Although this pharmacological group should notThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ant to establish its pharmacokinetics and efficacy in
animals in which it could be employed. Enrofloxacin, 1-
cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihidro-
4-oxo-3-quinoline carboxylic acid, is a fluoroquinolone
exclusively developed to be used in veterinary medicine
[4,5]. It is characterized by a low host toxicity, a high bio-
availability, an excellent tissue penetration, a long serum
half-life and a broad antibacterial spectrum together with
a high bactericidal activity against major pathogenic bac-
teria (both Gram-positive and Gram-negative) and intra-
cellular microorganisms found in sick animals [6,7].
The pharmacokinetics of enrofloxacin have been
widely described in several species including cattle
[8-11], buffaloes [12,13], sheep [14-16] and goats
[5,17,18]. In most of these species enrofloxacin shows
good absorption after parenteral administration, al-
though oral absorption drops to approximately 10% in
adult ruminants [19]. This drug exhibits a large volume
of distribution, suggesting wide tissue penetration, and a
terminal half-life of 2–6 h. Furthermore, enrofloxacin is
partially metabolized in the liver to ciprofloxacin, a pri-
mary metabolite which is a potent antimicrobial agent
itself [8].
It is well known that the strategies to control mastitis
include teat dip disinfection, milking procedures and se-
lective dry-off therapy, but studies on the effectiveness
of intramammary antimicrobial drugs are especially im-
portant, as many antimicrobial drugs are often adminis-
tered directly through the streak canal to treat or
prevent clinical or subclinical mastitis in dairy sheep. Re-
garding intramammary administration, to establish ra-
tional therapeutic dosage regimens, it is necessary to
determine drug concentrations achieved within the
udder and if these concentrations are sufficient to kill or
inhibit microorganism growth, taking into account that
drug distribution in tissue udder can vary according to
its liposolubility, its affinity for the tissue and the formu-
lation or the vehicle used. Milk and blood sampling are
often employed in vivo to assess local concentrations for
practical, ethical and economic reasons, although drug
concentrations at different areas of the udder cannot be
estimated in this way. In a previous study [20] we have
developed an ex vivo model of isolated and perfused
udder in sheep to investigate the pharmacokinetic be-
havior of enrofloxacin. In order to complete this former
one, the objective of the present study was to determine
plasma and tissue mammary gland concentrations of
enrofloxacin in healthy sheep after single intramammary
administration of 1 g enrofloxacin (1 g drug/5 g
ointment) to evaluate, on one hand, the degree of distri-
bution of enrofloxacin in the mammary gland and, on
the other one, the transfer of this drug to systemic circu-
lation. Moreover, the study will allow us to confirm thevalidity of the isolated and perfused model previously
carried out in sheep.
Methods
Animals
The study was carried out in six healthy female lactating
Spanish Assaf sheep weighing 45–57 kg and aged 4–5
years. Sheep were acclimatized and fed with an
antibacterial-free diet of alfalfa hay and pelleted feed
concentrate, and unlimited access to water and saltlick.
The Institutional Animal Care and Use Committee of
the University of León approved in advance all animal
procedures described here.
Clinical signs of mastitis, changes in milk or skin
lesions were not observed in any gland. Sheep were
completely milked previously to drug administration.
Intramammary administration was made through teat
with a single injector containing an enrofloxacin suspen-
sion (1 g of enrofloxacin/5 g of ointment) via the teat
canal, massaging afterwards into the gland cistern. Oint-
ment was administered only in one gland. Enrofloxacin
preparation was developed by Syva S.A. Laboratories
(Leon, Spain), and it is still at the research stage. Up to
date, and to our knowledge, there is no enrofloxacin
medicine for intramammary use.
Blood samples (10 mL) were collected into heparinized
vacuum tubes from a catheter laid in the jugular vein
just prior to drug administration, and at 30, 60, 90, 120,
150 and 180 min. Plasma was immediately separated by
centrifugation (1500 rpm for 20 min).
After 180 min sampling time, sheep were slaughtered
with the following protocol: sedation was carried out
with propofol (Propovet (10 mg/mL), Esteve, Barcelona,
Spain) (3 mg/kg, intravenous (IV) route) prior to admin-
istration of the euthanasia medicine containing embu-
tramide, mebezonium iodide and tetracaine hydrocloride
(T-61©, Merck Sharp & Dohme Animal Health, Salamanca,
Spain) (100 mg/kg, IV route). Samples of glandular tissue
were obtained at four different distances (2, 4, 6 and 8 cm)
from the base of the teat. All plasma and tissue samples
were frozen at −20°C and stored at −80°C until analysis.
Analysis of enrofloxacin concentrations
Enrofloxacin concentrations in plasma and glandular
tissue samples were measured by reversed phase high
performance liquid chromatography (HPLC) with UV
detection (LC Module I Plus, Waters Corporation,
Mildford, MA, USA). 1 mL plasma sample was deprotei-
nized with 0.5 mL 10% acetic acid, centrifuging at
3000 rpm for 10 min. Samples were then extracted and
purified according to a method previously reported [21]
with minor modifications. Mammary tissue samples
were also extracted and purified using a method previ-
ously described [22] with minor modifications. 4 mL
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nized at 13500 rpm for 30 seconds (Ultra-Turrax T-25,
IKA Works Inc, Wilmington, OH). 4 mL dichlorome-
tane and 0.5 mL sodium phosphate buffer 0.5 M
(pH= 7.5) were then added to homogenate, which was
shaken and centrifuged at 2500 rpm for 10 min. The or-
ganic phase was collected and mixed with 1 mL NaOH
0.5 M, centrifuging again at 2500 rpm for 10 min. This lat-
ter step was repeated twice, collecting the aqueous phase,
which was injected into the chromatograph.
Chromatographic analysis was carried out with a sep-
aration Nova Pak C18 column (4 μm, 250 × 4 mm)
(Waters Corporation, Mildford, MA, USA) at room
temperature. The mobile phase consisted of a mixture of
a solution of sodium acetate (pH 4.7; 0.1 M) and aceto-
nitrile 60:40 (v/v), with pH adjusted to 5 by addition of
acetic glacial acid. The flow rate of the mobile phase was
1 mL/min, and the wavelength was set at 278 nm. Under
these conditions, the retention time of enrofloxacin was
2.68 min. Recovery was 73.5 ± 9.1% and 83.8 ± 7.9% in
tissue and plasma samples, respectively. Interday and
intraday accuracy and precision were within 10%. The
limit of quantification was 0.08 μg/mL in both plasma
and tissue and the limit of detection was 0.04 μg/mL in
plasma and 0.08 μg/mL in tissue.
Statistical evaluation
Data were reported as mean ± standard deviation
(mean ± SD) or median and quartiles. Normality of
the data and uniformity of the variance were determined
by asymmetry and Levene’s test, respectively. When dataFigure 1 Plasma enrofloxacin concentrations after intramammary adm
containing 1 g enrofloxacin/5 g ointment. Data are given as mean ± SD (sewere normally distributed two-way ANOVA and Duncan
test were used to evaluate the significance of differences in
drug concentrations of treated udders. If data were not
normally distributed, Friedman and Wilcoxon tests were
then employed. A value of P ≤ 0.05 was considered as level
of significance for all analyses.
Results
Mean enrofloxacin plasma concentrations after intra-
mammary administration are shown in Figure 1. Con-
centrations measured were low in these first 3 h after
administration, remaining nearly constant from 60 min
onwards. At 180 min concentrations ranged from 0.077
to 0.569 μg/mL. In one of the animals the drug was not
detected at any sampling time, and at 30 min enrofloxa-
cin was detected only in two sheep.
Regarding tissue concentrations, Figure 2 summarizes
enrofloxacin concentrations in glandular tissue taken at
180 min at the different sampling heights. Animals
were evaluated hourly during the assay, and neither
general signs nor local irritation reactions (swelling or
tissue hardening) were observed. Drug concentrations
always decreased with increasing distance from the teat.
Enrofloxacin concentrations were 356.6 ± 109.3 μg/g tis-
sue near the teat (2 cm distance), declining to 172.34 ±
97.3; 113.06 ± 81.8 and 95.60 ± 74.0 μg/g at 4; 6 and
8 cm distances, respectively. At this latter point, at
the base of the udder, values ranged from 8.42 to
188.84 μg/g. Significant differences were found among
enrofloxacin concentrations determined at 2 cm and those
measured at the other heights (Duncan test, P ≤ 0.05).inistration to 6 sheep. Administration was made with an injector
milogarithmic scale).
Figure 2 Enrofloxacin concentrations in glandular tissue after intramammary administration to 6 sheep. Administration was made with
an injector containing 1 g enrofloxacin/5 g ointment. Samples were taken at constant vertical distances from the base of the teat. Significant
differences were found between concentrations determined at 2 cm and at the rest of the heights. Theoretical values predicted with the
equation Concentration = 478.804 · e-0.251 · height are also included (short dash line). Data are given as box plots with median and quartiles
(semilogarithmic scale).
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were also compared with those determined in the
ex vivo isolated and perfused udders after intramammary
administration [20], and modelled. In both, healthy
sheep and isolated udders, the best fit was obtained with
a decreasing monoexponential model, described by the
following equations:
Ex vivo model : Concentration
¼ 177:776 :e‐0:251 : height r2 ¼ 0:924; p ¼ 0:039 
Healthy sheep : Concentration
¼ 478:804 : e‐0:219 : height r2 ¼ 0:950; p ¼ 0:025 
In both equations the slopes are very similar (0.251 for
the ex vivo model and 0.219 for healthy sheep), which
would reveal a similar diffusion kinetics. Thus, taking
into account the coefficients obtained in both equations,
it would be possible to predict concentrations in alive
animals at different heights of mammary gland by multi-
plying ex vivo tissue concentrations by 2.693 or by using
a new equation obtained from that used to describe the
ex vivo model concentrations, multiplying the intercept
(177.776) by 2.7:
Concentration ¼ 478:804 : e‐0:251 : height
Figure 2 shows the close correspondence among the
theoretical enrofloxacin concentrations in mammary
gland predicted with this latter equation and theexperimental values determined in the same tissue
but in healthy animals.
Discussion
As expected, enrofloxacin plasma concentrations were
low after intramammary administration, showing that
most drug remains in the udder carrying out its bacteri-
cidal action. These low concentrations would minimize
the risk for consumers due to residues in meat or in
other tissues. The drug was detected after 30 min ad-
ministration only in two animals, which would indicate
that in the other sheep the rate of absorption was slower
that in these two animals. In one sheep absorption
was too small to determine detectable levels in plasma
at any sampling time. On the other hand, plasma drug
concentrations determined in healthy animals were al-
ways lower than those obtained in Tyrode solution
with the ex vivo model of isolated and perfused sheep
udder [20]. This may be due to the fact that the
ex vivo model exhibits a lower volume of distribution
and it does not reflect the actual physiological condi-
tions of drug elimination, as it lacks the organs in-
volved in elimination process such as liver or kidneys.
On the other hand, in healthy animals, although a
greater transfer of drug from mammary gland into the
bloodstream is expected in comparison with the
ex vivo model, the proportional increase in the elimin-
ation process should explain the lower enrofloxacin
plasma levels.
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tissue, they decreased progressive and exponentially with
increased vertical distance from the base of the teat. The
high variability obtained in tissue concentrations is
consistent with those results indicated in other similar
studies [23-27], and it can be due to interindividual vari-
ations related to gland size or milk secretion volume
(related to the degree of drug dilution), even though ani-
mals were selected according to similar conformation
and udder size, level of milk production or days in milk.
Enrofloxacin concentrations determined reflect a good
distribution of this drug in the entire mammary gland.
We have chosen four locations per quarter as they rep-
resent the minimum number of samples to assess drug
distribution because antimicrobials distribute unevenly
in glandular tissue [23,28].
Comparing with drug concentrations determined in
the ex vivo model developed in sheep [20], mammary
concentrations in healthy animals are higher than those
quantified in the ex vivo model. Again, these differences
could be due to disparities between the model and the
physiological conditions of healthy animals: composition
of Tyrode solution is not exactly similar to blood com-
position, and there could also be differences between
perfusion flow in the ex vivo model and blood flow in
alive animals. Moreover, the ex vivo model is static
whereas alive sheep were allowed to move during the
entire duration of the sampling time. Finally, the formu-
lation used can also have an influence on the distribu-
tion of antimicrobials administered locally into the
bovine udder. All these factors could contribute to a
greater diffusion of drug within the mammary gland in
alive sheep.
Data on drug distribution in mammary gland are
scarce, and drug concentration in milk after intramam-
mary administration cannot be used to estimate drug
concentration in udder tissue [25]. At present two differ-
ent approaches have been followed. On one hand,
ex vivo perfused models have been designed to establish
drug concentrations in bovine and ovine udders
[20,24,25,29] but it remained unclear if they accurately
reflect the situation in vivo [26,30]. On the other one,
anesthetized alive animals have been used to determine
tissue distribution, but its major inconvenient is that
quarters can be sampled only once [31], which actually
limits its usage. We have chosen an intermediate ap-
proach to evaluate if drug concentrations determined in
healthy animals are comparable to those obtained in the
ex vivo perfused model [20]. In this case, we have fixed
180 min as sampling time to collect tissue samples as it
is the time for which the isolated and perfused udders
remained viable in sheep.
Finally, to establish if sufficient antibacterial concentra-
tions are reached in the target tissue after enrofloxacinintramammary administration, a pharmacokinetic/
pharmacodynamic (PK/PD) evaluation was also devel-
oped to assess treatment effectivity. Regarding its
antibacterial activity, enrofloxacin, as any fluoroquinolone,
has a concentration-dependent activity. Minimal inhibitory
concentrations that inhibits 90% of bacterial isolates
(MIC90) have been categorized as sensitive (<0.25 μg/mL),
intermediate (0.5-1 μg/mL) or resistant (>2 μg/mL) [32]. In
sheep bacterial isolates a MIC of 0.5 μg/mL has been estab-
lished for Mycoplasma agalactiae [33]. MIC values deter-
mined in cattle isolates are 0.12 μg/mL for Escherichia coli
[34], 0.125 μg/mL for Mannheimia haemolytica [35], and
0.25 μg/mL for Staphylococcus aureus [36-38] and Strepto-
coccus spp. [39]. In all the animals MIC were exceeded in
the entire glandular tissue following intramammary admin-
istration, whereas in plasma samples mean enrofloxacin
concentrations did not achieve the MIC fixed for Myco-
plasma agalactiae.
Moreover, we have chosen the PK/PD index Concen-
tration/MIC (C/MIC) > 8–10 [40,41] to assess if suffi-
cient antibacterial concentrations are reached after
intramammary administration within the glandular tis-
sue. After 3 h drug diffusion, enrofloxacin concentra-
tions in the entire glandular tissue were always more
than 8–10 times above the MIC established for the main
pathogens causing mastitis in sheep. In the base of the
udder, C/MIC was 191.20 for M. agalactiae; 382.40 for
S. aureus and Streptococcus spp.; 764.80 for M. haemoly-
tica and 796.67 for E. coli. Regarding plasma concentra-
tions, intramammary treatment would not be actually
effective against any microorganism, as C/MIC was
always lower than 8.
Finally, and with respect to the potential presence of
enrofloxacin residues in both tissues or milk after intra-
mammary administration, the study has shown that the
transference of the drug from the mammary gland to
plasma is low, which would diminish the risk of drug
residues in meat. In mammary gland tissue, high enro-
floxacin concentrations have been determined. Thus,
further studies are necessary to ensure that the drug has
been completely excreted from the animal, prior to
dairy/meat products being available for consumers, in
order to avoid the emergence and dissemination of
harmful bacteria resistant to fluoroquinolones and/or
undesirable effects on consumers.
Conclusions
Fluoroquinolones should be only used to treat serious
infections with bacteria resistant to other antibacterial
agents. To our knowledge, this is the first time that tis-
sue distribution of enrofloxacin in the mammary gland
and its degree of systemic absorption following intra-
mammary administration have been established. The
study provides complementary data on enrofloxacin
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lations employed to treat mastitis in this species. The
drug shows a low transfer to systemic circulation and a
wide distribution throughout the udder, achieving in the
entire gland adequate concentrations against the major
mastitis pathogens in sheep. Thus, enrofloxacin may be
a suitable option for treating this disease in dairy sheep
following intramammary administration although further
studies are needed to ensure its efficacy and safety.
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